Authors/Disclosures
|
Brian C. Healy
|
The institution of Mr. Healy has received research support from Analysis Group. The institution of Mr. Healy has received research support from Bristol-Myers Squibb. The institution of Mr. Healy has received research support from Verily Life Sciences. The institution of Mr. Healy has received research support from Novartis. The institution of Mr. Healy has received research support from Merck Serono. The institution of Mr. Healy has received research support from Genzyme. |
|
|
No disclosure on file |
|
Charles R. Guttmann
|
Charles R.G. Guttmann has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sintetica SA. Charles R.G. Guttmann has received stock or an ownership interest from Alnylam. Charles R.G. Guttmann has received stock or an ownership interest from Roche. Charles R.G. Guttmann has received stock or an ownership interest from Novartis. Charles R.G. Guttmann has received stock or an ownership interest from Arrowhead Pharmaceuticals. Charles R.G. Guttmann has received stock or an ownership interest from Protalix. Charles R.G. Guttmann has received stock or an ownership interest from Promethee. Charles R.G. Guttmann has received stock or an ownership interest from GSK. Charles R.G. Guttmann has received stock or an ownership interest from Sangamo. Charles R.G. Guttmann has received stock or an ownership interest from Alcon. Charles R.G. Guttmann has received stock or an ownership interest from Cocrystal Pharma. The institution of Charles R.G. Guttmann has received research support from NIH. The institution of Charles R.G. Guttmann has received research support from McGill University. The institution of Charles R.G. Guttmann has received research support from National Multiple Sclerosis Society. The institution of Charles R.G. Guttmann has received research support from BrightFocus Foundation. The institution of Charles R.G. Guttmann has received research support from National Multiple Sclerosis Society. The institution of Charles R.G. Guttmann has received research support from University of Connecticut Health Center. The institution of Charles R.G. Guttmann has received research support from U.S. Office of Naval Research. |
|
Mehul P. Sampat, PhD
|
No disclosure on file |
|
Howard L. Weiner, MD
(Brigham and Women'S Hospital)
|
Dr. Weiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Weiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medday Pharmaceuticals. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for vTv Therapeutics. Dr. Weiner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Tiziana Life Sciences. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for vTv Therapeutics. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medday Pharmaceuticals. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for vTv Therapeutics. Dr. Weiner has stock in vTv Therapeutics. The institution of Dr. Weiner has received research support from National Institute of Health. The institution of Dr. Weiner has received research support from National MS Society. The institution of Dr. Weiner has received research support from Genzyme Corp. The institution of Dr. Weiner has received research support from Genentech, Inc. . The institution of Dr. Weiner has received research support from Verily Life Sciences LLC. The institution of Dr. Weiner has received research support from EMD Serono, Inc.. |
|
David A. Hafler, MD, FAAN
(Yale University School of Medicine, Dept of Neurology)
|
Dr. Hafler has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Hafler has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genetech. Dr. Hafler has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Hafler has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Joint Commission International. |
|
Philip De Jager, MD, PhD
(Columbia University Irving Medical Center)
|
Dr. De Jager has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. De Jager has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Puretech. Dr. De Jager has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for roche. Dr. De Jager has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for biogen. The institution of Dr. De Jager has received research support from roche. The institution of Dr. De Jager has received research support from Biogen. The institution of Dr. De Jager has received research support from puretech. |
|
|
No disclosure on file |